Abstract
Plasminogen Activator Inhibitor-1 (PAI-1) is a multifunctional protein with the ability to not only regulate fibrinolysis through inhibition of plasminogen activation, but also cell signaling events which have direct downstream effects on cell function. Elevated plasma levels of this protein have been shown to have profound effects on the development and progression of cardiovascular diseases. However, results from a number of studies, especially those using PAI-1 deficient mouse models, have demonstrated that its function is ambiguous, with evidence of both preventing and enhancing various disease states. A number of lifestyle changes and pharmacological reagents have been identified that can regulate PAI-1 levels or function. Those reagents that target function are focused on its ability to regulate plasmin formation, and have been studied in in vivo models of thrombosis. Further investigations involving regulation of cell function could potentially resolve paradoxical issues associated with the function of this protein in regulating cardiovascular disease.
Keywords: Plasminogen activator inhibitor-1, gene knock out mice, cardiovascular disease, angiotensin converting enzyme inhibitor, myocardial infarction, atherosclerosis, cardiac fibrosis, DNAzyme, statin, proteases
Current Drug Targets
Title: Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease
Volume: 12 Issue: 12
Author(s): Victoria A. Ploplis
Affiliation:
Keywords: Plasminogen activator inhibitor-1, gene knock out mice, cardiovascular disease, angiotensin converting enzyme inhibitor, myocardial infarction, atherosclerosis, cardiac fibrosis, DNAzyme, statin, proteases
Abstract: Plasminogen Activator Inhibitor-1 (PAI-1) is a multifunctional protein with the ability to not only regulate fibrinolysis through inhibition of plasminogen activation, but also cell signaling events which have direct downstream effects on cell function. Elevated plasma levels of this protein have been shown to have profound effects on the development and progression of cardiovascular diseases. However, results from a number of studies, especially those using PAI-1 deficient mouse models, have demonstrated that its function is ambiguous, with evidence of both preventing and enhancing various disease states. A number of lifestyle changes and pharmacological reagents have been identified that can regulate PAI-1 levels or function. Those reagents that target function are focused on its ability to regulate plasmin formation, and have been studied in in vivo models of thrombosis. Further investigations involving regulation of cell function could potentially resolve paradoxical issues associated with the function of this protein in regulating cardiovascular disease.
Export Options
About this article
Cite this article as:
A. Ploplis Victoria, Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease, Current Drug Targets 2011; 12 (12) . https://dx.doi.org/10.2174/138945011797635803
DOI https://dx.doi.org/10.2174/138945011797635803 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Bacterial Drug Discovery Using Systems Biology
Mini-Reviews in Medicinal Chemistry Calcium Related Genes in Dogs as Potential Cardiac Biomarkers for the Detection of Chronic Mitral Valve Disease
Recent Patents on Biomarkers Atrial Fibrillation in Heart Failure: An Innocent Bystander?
Current Cardiology Reviews Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Adrenomedullins: Therapeutic Potential in Cardiovascular Disease
Current Hypertension Reviews Treating Dyslipidemias: Is Inflammation the Missing Link?
Medicinal Chemistry Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease
Current Pharmaceutical Design Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations
Current Clinical Pharmacology Longevity Depends on a Balance Between Proinflammatory and Anti-Inflammatory Factors: Use of Tcms and Natural Products
Current Drug Discovery Technologies Blood Atherogenicity as a Target for Anti-atherosclerotic Therapy
Current Pharmaceutical Design The Predictive Value of Lipid Markers in Vascular Disease
Current Pharmaceutical Design Chemical Constituents of the Genus Prunus and their Medicinal Properties
Current Medicinal Chemistry Cardiovascular Biology of Interleukin-6
Current Pharmaceutical Design The Right Ventricle: Biologic Insights and Response to Disease: Updated
Current Cardiology Reviews Perinatal and Neonatal Outcomes of Lithium-Treated and Untreated Bipolar Women During Pregnancy: A Review of Present Literature
Current Psychopharmacology On the Involvement of H2S in Nitroso Signaling and Other Mechanisms of H2S Action
Current Pharmaceutical Biotechnology Patent Selections
Recent Patents on Biomarkers Malnutrition in Patients with End-Stage Renal Disease - Anorexia,Cachexia and Catabolism
Current Nutrition & Food Science Chemical Biology: Past, Present and Future
Current Chemical Biology